Takahashi I, Ohmoto E, Nakada H, Inagaki N, Nonaka K, Takeuchi M, Osada K, Tsurumi N, Uchida K, Yorimitsu S
Dept. of Medicine, Okayama University Medical School.
Gan To Kagaku Ryoho. 1988 Jan;15(1):159-62.
Five cases of hypoplastic acute myelocytic leukemia were treated with an IgG-melphalan conjugate, K-18. Eight tablets of K-18, containing 30 mg per tablet, were given daily. One patient, a 68-year-old female, obtained complete remission with a duration of 1.5 + months. Among the four remaining patients without remission, one showed a decrease in leukemic cells in the peripheral blood. No side effects of K-18 were observed except in one patient, showing a slight increase in serum GOT and GPT levels. Further studies with a large group will be necessary to clarify the effect of this drug on hypoplastic leukemia.
五例低增生性急性髓细胞白血病患者接受了一种IgG-美法仑偶联物K-18的治疗。每天服用八片K-18，每片含30毫克。一名68岁女性患者获得完全缓解，缓解期为1.5多个月。其余四名未缓解的患者中，一名患者外周血白血病细胞减少。除一名患者血清谷草转氨酶和谷丙转氨酶水平略有升高外，未观察到K-18的副作用。有必要对一大组患者进行进一步研究，以阐明该药物对低增生性白血病的疗效。
